Institutional members access full text with Ovid®

Share this article on:

Myxoinflammatory Fibroblastic Sarcoma: Clinical, Imaging, Management and Outcome in 29 Patients

Kumar, Rajendra MD, FACR; Lefkowitz, Robert A. MD; Neto, Afranio Dos Reis Teixeira MD

Journal of Computer Assisted Tomography: January 2017 - Volume 41 - Issue 1 - p 104–115
doi: 10.1097/RCT.0000000000000490
Musculoskeletal Radiology

Objective This retrospective study was undertaken to highlight clinical and magnetic resonance imaging features of myxoinflammatory fibroblastic sarcoma.

Methods The clinical records of 29 patients (14 men and 15 women) were analyzed.

Results The soft tissue tumors involved hand, wrist, foot and ankle in 21 patients, more proximal extremities in 7 patients, and neck in 1 patient. The tumors were subcutaneous in 11 patients, and intramuscular in 15 patients. On magnetic resonance imaging, these tumors had nonspecific features suggestive of benign and malignant lesions. An unusual tumor in hand indicated infection, whereas an intraarticular knee tumor mimicked pigmented villonodular synovitis. All tumors were surgically resected.

Conclusions Myxoinflammatory fibroblastic sarcoma, a rare low-grade subcutaneous soft tissue tumor of distal extremities with high local recurrence after resection can mimic several benign and malignant lesions on histopathology and imaging. Rarely, it can arise in muscles and tendons, occur in nonacral sites, be aggressive, and even metastasize. In most cases, surgical resection with wide margins can be curative with low local recurrence.

From the *Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX; and †Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Received for publication February 25, 2016; accepted May 23, 2016.

Correspondence to: Rajendra Kumar, MD, FACR, Department of Diagnostic Imaging, UT MD Anderson Cancer, 1515 Holcombe Blvd., FCT 15.6026, Unit 1475, Houston, TX 77030-4009 (e-mail:

The authors declare no conflict of interest.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.